Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 82
Filtrar
1.
Sci Rep ; 12(1): 19209, 2022 11 10.
Artigo em Inglês | MEDLINE | ID: mdl-36357507

RESUMO

Nowadays, exome sequencing is a robust and cost-efficient genetic diagnostic tool already implemented in many clinical laboratories. Despite it has undoubtedly improved our diagnostic capacity and has allowed the discovery of many new Mendelian-disease genes, it only provides a molecular diagnosis in up to 25-30% of cases. Here, we comprehensively evaluate the results of a large sample set of 4974 clinical exomes performed in our laboratory over a period of 5 years, showing a global diagnostic rate of 24.62% (1391/4974). For the evaluation we establish different groups of diseases and demonstrate how the diagnostic rate is not only dependent on the analyzed group of diseases (43.12% in ophthalmological cases vs 16.61% in neurological cases) but on the specific disorder (47.49% in retinal dystrophies vs 24.02% in optic atrophy; 18.88% in neuropathies/paraparesias vs 11.43% in dementias). We also detail the most frequent mutated genes within each group of disorders and discuss, on our experience, further investigations and directions needed for the benefit of patients.


Assuntos
Atrofia Óptica , Distrofias Retinianas , Humanos , Exoma/genética , Sequenciamento do Exoma , Distrofias Retinianas/genética , Atrofia Óptica/genética
2.
Hum Genet ; 140(12): 1665-1678, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34448047

RESUMO

Syndromic retinal diseases (SRDs) are a group of complex inherited systemic disorders, with challenging molecular underpinnings and clinical management. Our main goal is to improve clinical and molecular SRDs diagnosis, by applying a structured phenotypic ontology and next-generation sequencing (NGS)-based pipelines. A prospective and retrospective cohort study was performed on 100 probands with an a priori diagnosis of non-Usher SRDs, using available clinical data, including Human Phenotype Ontology annotation, and further classification into seven clinical categories (ciliopathies, specific syndromes and five others). Retrospective molecular diagnosis was assessed using different molecular and bioinformatic methods depending on availability. Subsequently, uncharacterized probands were prospectively screened using other NGS approaches to extend the number of analyzed genes. After phenotypic classification, ciliopathies were the most common SRD (35%). A global characterization rate of 52% was obtained, with six cases incompletely characterized for a gene that partially explained the phenotype. An improved characterization rate was achieved addressing prospective cases (83%) and well-recognizable syndrome (62%) subgroups. The 27% of the fully characterized cases were reclassified into a different clinical category after identification of the disease-causing gene. Clinical-exome sequencing is the most appropriate first-tier approach for prospective cases, whereas whole-exome sequencing and bioinformatic reanalysis increases the diagnosis of uncharacterized retrospective cases to 45%, mostly those with unspecific symptoms. Our study describes a comprehensive approach to SRDs in daily clinical practice and the importance of thorough clinical assessment and selection of the most appropriate molecular test to be used to solve these complex cases and elucidate novel associations.


Assuntos
Oftalmopatias Hereditárias/diagnóstico , Ontologia Genética , Sequenciamento de Nucleotídeos em Larga Escala , Doenças Retinianas/diagnóstico , Ciliopatias/genética , Estudos de Coortes , Oftalmopatias Hereditárias/genética , Feminino , Estudos de Associação Genética , Testes Genéticos , Humanos , Masculino , Técnicas de Diagnóstico Molecular , Mutação , Fenótipo , Estudos Prospectivos , Doenças Retinianas/genética , Estudos Retrospectivos , Síndrome
3.
Sci Rep ; 11(1): 5697, 2021 03 11.
Artigo em Inglês | MEDLINE | ID: mdl-33707547

RESUMO

Despite the improved accuracy of next-generation sequencing (NGS), it is widely accepted that variants need to be validated using Sanger sequencing before reporting. Validation of all NGS variants considerably increases the turnaround time and costs of clinical diagnosis. We comprehensively assessed this need in 1109 variants from 825 clinical exomes, the largest sample set to date assessed using Illumina chemistry reported. With a concordance of 100%, we conclude that Sanger sequencing can be very useful as an internal quality control, but not so much as a verification method for high-quality single-nucleotide and small insertion/deletions variants. Laboratories might validate and establish their own thresholds before discontinuing Sanger confirmation studies. We also expand and validate 23 copy number variations detected by exome sequencing in 20 samples, observing a concordance of 95.65% (22/23).


Assuntos
Exoma/genética , Sequenciamento de Nucleotídeos em Larga Escala , Mutação/genética , Variações do Número de Cópias de DNA/genética , Humanos , Reprodutibilidade dos Testes
4.
Actas Dermosifiliogr (Engl Ed) ; 109(2): 104-122, 2018 Mar.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-29180129

RESUMO

Epidermolysis bullosa (EB) is a rare genetic disease that causes mucocutaneous fragility. It comprises a clinically and genetically heterogeneous group of disorder characterized by spontaneous or contact/friction-induced blistering. EB is classified into 4 types-simplex, junctional, dystrophic, and Kindler syndrome-and 30 subtypes. The disease is caused by defects in proteins implicated in dermal-epidermal adhesion. At least 19 genes have been characterized and more than 1000 mutations identified, thus rendering diagnosis complex. Molecular diagnosis of EB is the last stage of a laborious process that starts with a detailed clinical history compilation and careful procurement of a skin fresh biopsy that includes an area where the epidermis detaches from the dermis. The detachment area makes it possible to establish the cleavage plane by antigen mapping and, in the best scenario, to identify a single candidate gene to search for pathogenic mutations. The results of the molecular diagnosis enable the physician to provide appropriate genetic counseling (inheritance pattern, risk of recurrence, and options for prenatal and preimplantation diagnosis) and implement subsequent preventive programs, as well as to establish a reasonable clinical prognosis facilitating access to specific therapy and rehabilitation. Lastly, molecular diagnosis is essential for the participation of patients in clinical trials, a critical issue given the current incurable status of EB. The present guidelines aim to disseminate the procedure for diagnosing EB in our laboratory and thus avoid suboptimal or incomplete clinical diagnoses. The recommendations we provide are the result of more than 10 years' experience in the molecular diagnosis of EB in Spain.


Assuntos
Epidermólise Bolhosa/diagnóstico , Técnicas de Diagnóstico Molecular/normas , Epidermólise Bolhosa/genética , Humanos , Guias de Prática Clínica como Assunto
5.
Neurologia ; 32(6): 377-385, 2017.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-26968818

RESUMO

INTRODUCTION: Duchenne muscular dystrophy (DMD) is a severe X-linked recessive neuromuscular disease that affects one in 3500 live-born males. The total absence of dystrophin observed in DMD patients is generally caused by mutations that disrupt the reading frame of the DMD gene, and about 80% of cases harbour deletions or duplications of one or more exons. METHODS: We reviewed 284 cases of males with a genetic diagnosis of DMD between 2007 and 2014. These patients were selected from 8 Spanish reference hospitals representing most areas of Spain. Multiplex PCR, MLPA, and sequencing were performed to identify mutations. RESULTS: Most of these DMD patients present large deletions (46.1%) or large duplications (19.7%) in the dystrophin gene. The remaining 34.2% correspond to point mutations, and half of these correspond to nonsense mutations. In this study we identified 23 new mutations in DMD: 7 large deletions and 16 point mutations. CONCLUSIONS: The algorithm for genetic diagnosis applied by the participating centres is the most appropriate for genotyping patients with DMD. The genetic specificity of different therapies currently being developed emphasises the importance of identifying the mutation appearing in each patient; 38.7% of the cases in this series are eligible to participate in current clinical trials.


Assuntos
Distrofia Muscular de Duchenne/genética , Adulto , Análise Mutacional de DNA , Distrofina/genética , Deleção de Genes , Genótipo , Humanos , Masculino , Distrofia Muscular de Duchenne/epidemiologia , Espanha/epidemiologia
6.
Mol Genet Metab Rep ; 9: 79-85, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27872820

RESUMO

BACKGROUND: Fundación Jiménez Díaz (FJD) is a reference center for genetic diagnosis of Gaucher disease (GD) in Spain. Genetic analyses of acid ß-glucosidase (GBA) gene using different techniques were performed to search for new mutations, in addition to those previously and most frequently found in the Spanish population. Additionally, the study of the chitotriosidase (CHIT1) gene was used to assess the inflammatory status of patients in the follow-up of enzyme replacement therapy (ERT). We present the genetic data gathered during the last nine years at FJD. METHODS: Blood samples from patients with suspected GD were collected for enzymatic and genetic analyses. The genetic analysis was performed on DNA from 124 unrelated suspected cases and 57 relatives from 2007 to 2015, starting with a mutational screening kit, followed by Sanger sequencing of the entire gene and other techniques to look for deletions. CHIT1 was also studied to assess the reliability of this biomarker. RESULTS: In 46 out of 93 GD patients (49.5%) the two mutant alleles were found. We detected 21 different mutations. The most common mutation was N370S (c.126A > G; p.Asp409Ser current nomenclature) (in 50.5% of patients), followed by L444P (c.1448T > C; p.Leu483Pro current nomenclature) (in 24.7%). The most common heterozygous compound genotype observed (18.3%) was c.1226A > G/c.1448T > C (N370S/L444P). Two novel mutations were found (del. Ex.4-11 and c.1296G > T; pW432C), as well as p.S146L, only once previously reported. Two patients showed the homozygous state for the duplication of CHIT1. CONCLUSION: N370S and L444P are the most common mutations and other mutations associated to Parkinson's disease have been observed. This should be taken into account in the genetic counseling of GD patients.

7.
Neuromuscul Disord ; 26(2): 153-9, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26782015

RESUMO

Rapsyn (RAPSN) mutations are a common cause of postsynaptic congenital myasthenic syndromes. We present a comprehensive description of the clinical and molecular findings of ten patients with CMS due to mutations in RAPSN, mostly with a long-term follow-up. Two patients were homozygous and eight were heterozygous for the common p.Asn88Lys mutation. In three of the heterozygous patients we have identified three novel mutations (c.869T > C; p.Leu290Pro, c.1185delG; p.Thr396Profs*12, and c.358delC; p.Gln120Serfs*8). In our cohort, the RAPSN mutations lead to a relatively homogeneous phenotype, characterized by fluctuating ptosis, occasional bulbar symptoms, neck muscle weakness, and mild proximal muscle weakness with exacerbations precipitated by minor infections. Interestingly, episodic exacerbations continue to occur during adulthood. These were characterized by proximal limb girdle weakness and ptosis, and not so much by respiratory insufficiency after age 6. All patients presented during neonatal period and responded to cholinergic agonists. In most of the affected patients, additional use of 3,4-diaminopyridine resulted in significant clinical benefit. The disease course is stable except for intermittent worsening.


Assuntos
Inibidores da Colinesterase/farmacologia , Progressão da Doença , Proteínas Musculares/genética , Síndromes Miastênicas Congênitas/genética , Síndromes Miastênicas Congênitas/fisiopatologia , Bloqueadores dos Canais de Potássio/farmacologia , 4-Aminopiridina/administração & dosagem , 4-Aminopiridina/análogos & derivados , 4-Aminopiridina/farmacologia , Adolescente , Adulto , Amifampridina , Criança , Pré-Escolar , Inibidores da Colinesterase/administração & dosagem , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Mutação , Síndromes Miastênicas Congênitas/tratamento farmacológico , Fenótipo , Bloqueadores dos Canais de Potássio/administração & dosagem , Brometo de Piridostigmina/administração & dosagem , Brometo de Piridostigmina/farmacologia , Adulto Jovem
9.
Arch Soc Esp Oftalmol ; 88(4): 145-52, 2013 Apr.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-23597644

RESUMO

INTRODUCTION: Aniridia is a panocular disorder which occurs in 1/50,000 to 1/100,000 live births and can appear either in isolated form or in the context of a syndrome. Isolated aniridia is inherited as an autosomal dominant condition and is caused by mutations of the PAX6 gene. A variety of techniques and methodologies within molecular genetics and cytogenetics are used to study these mutations. OBJECTIVE: To identify the different aspects of this disease and to provide a guide for proper genetic diagnosis leading to improved clinical management of the disease. DEVELOPMENT: Aniridia is an autosomal dominant disease that primarily affects the iris, though it can impact most of the ocular structures. The disease is mainly caused by mutations in the PAX6 gene located on chromosome 11p13 which encodes a transcription factor that is involved in the development of the eye. Genetic analysis of aniridia is complex and requires the use of both molecular genetics and cytogenetics techniques. These procedures are indicated in all cases of aniridia. It is important bear certain clinical and technical aspects in mind prior to starting analysis or providing genetic counseling for patients and their families. CONCLUSIONS: The use of molecular genetic techniques in the genetic diagnosis of aniridia enables patients and their families to receive better clinical management.


Assuntos
Aniridia/genética , Aniridia/diagnóstico , Árvores de Decisões , Humanos , Guias de Prática Clínica como Assunto
10.
Arch. Soc. Esp. Oftalmol ; 88(4): 145-152, abr. 2013. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-111857

RESUMO

Introducción: La aniridia es una enfermedad panocular con una incidencia de entre 1/50.000 a 1/100.000 nacidos vivos, que puede presentarse de forma aislada o en el contexto de un síndrome. Presenta una herencia autosómica dominante y en la mayoría de los casos está causada por mutaciones en el gen PAX6, para cuyo estudio de mutaciones se emplea una gran variedad de técnicas y metodologías de genética molecular y citogenéticas. Objetivo: Recoger los distintos aspectos de esta enfermedad y ofrecer una guía para el adecuado diagnóstico genético que ayude a un mejor manejo clínico de la misma. Desarrollo: La aniridia es una enfermedad autosómica dominante que afecta fundamentalmente al iris, pero también puede afectar a la mayoría de las estructuras oculares. Está causada principalmente por mutaciones en el gen PAX6, ubicado en la región cromosómica 11p13, que codifica para una proteína reguladora de la transcripción imprescindible en el desarrollo del ojo. El análisis genético de la aniridia es complejo y requiere tanto de técnicas de genética molecular (secuenciación, CGH-array o MLPA) como citogenéticas (cariotipo y FISH). Este estudio está indicado en todos los casos de aniridia y es importante tener en cuenta ciertas consideraciones tanto clínicas como técnicas antes de abordar su análisis y el asesoramiento genético de los pacientes y familias afectados por esta enfermedad. Conclusiones: La aplicación de técnicas de genética molecular al diagnóstico genético de la aniridia permite un mejor manejo clínico tanto de los afectados como de sus familiares(AU)


Introduction: Aniridia is a panocular disorder which occurs in 1/50,000 to 1/100,000 live births and can appear either in isolated form or in the context of a syndrome. Isolated aniridia is inherited as an autosomal dominant condition and is caused by mutations of the PAX6 gene. A variety of techniques and methodologies within molecular genetics and cytogenetics are used to study these mutations. Objective: To identify the different aspects of this disease and to provide a guide for proper genetic diagnosis leading to improved clinical management of the disease. Development: Aniridia is an autosomal dominant disease that primarily affects the iris, though it can impact most of the ocular structures. The disease is mainly caused by mutations in the PAX6 gene located on chromosome 11p13 which encodes a transcription factor that is involved in the development of the eye. Genetic analysis of aniridia is complex and requires the use of both molecular genetics and cytogenetics techniques. These procedures are indicated in all cases of aniridia. It is important bear certain clinical and technical aspects in mind prior to starting analysis or providing genetic counseling for patients and their families. Conclusions: The use of molecular genetic techniques in the genetic diagnosis of aniridia enables patients and their families to receive better clinical management(AU)


Assuntos
Humanos , Masculino , Feminino , Aniridia/genética , Oftalmopatias/genética , Oftalmopatias/diagnóstico , Mutação/genética , Mutação/fisiologia , Glaucoma/genética , Estrabismo/complicações , Nistagmo Congênito/complicações , Fenótipo , Eletroforese/métodos , Eletroforese/tendências , Eletroforese
12.
Bone ; 51(4): 748-55, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22796417

RESUMO

We aimed to investigate the epidemiological determinants, clinical features, and genetic pattern of FOP in our country by evaluating the entire population of patients identified according to a combination of methods. To achieve this, 24 individuals were confirmed as FOP cases, 17 of whom were alive at the end of 2011 (point prevalence=0.36 × 10(-6)). The gender distribution (male/female ratio=13/11) and the concurrent range of ages (from 4 to 53 years; mean ± SD: 30.2 ± 13.8) are in agreement with similar reports. Twenty-one (87.5%) had characteristic congenital malformations of the big toe, and short thumbs were found in 65.2% of cases. In addition, other skeletal malformations such us fusion of the posterior elements of the cervical spine (89.0%), knee osteochondromas (71%), scoliosis (54.5%), and short and broad femoral neck (52.6%) were observed. All had developed mature ossicles of heterotopic bone in typical anatomic and temporal patterns, ranging in number from 1 to 17 (9.5 ± 3.9). Age at appearance of first ossifying lesion varied from 3 months to 15 years. Mean age at diagnosis was 7.3 ± 5.1 years and the average delay in reaching the correct diagnosis after the onset of heterotopic ossification was 2.7 years (range=0-12 years). Biopsy of the pre-osseous lesions was performed in 11 of 20 (55.0%), providing no useful information for the diagnosis of FOP. Seven of 18 (38.9%) reported some hearing loss, and 5 (27.8%) experienced diffuse thinning of the hair or were bald. No patient had relatives with a typical FOP clinical picture. Fourteen of the 16 cases which were genetically investigated displayed the single heterozygous mutation c.617G>A in exon 4 of the ACVR1 gene. One of the two patients who did not present with the canonical ACVR1 mutation showed a heterozygous mutation c.774G>C in exon 5 leading to the substitution of Arginine 258 with a serine. The other patient had a heterozygous c.774G>T substitution in exon 5 leading to the same amino acid change (p.Arg258Ser). These two patients had only nonspecific abnormalities of the great toe, lacked the typical anatomic and developmental pattern of heterotopic ossification, and shared a trend toward uncommon clinical features. These results provide new insight on the epidemiological and clinical traits of FOP, reinforcing the notion of its worldwide homogeneity. The molecular characterization of ACVR1 sequence variation will contribute to the understanding of the genetic profile of this devastating disease in different geographical areas.


Assuntos
Miosite Ossificante , Receptores de Ativinas Tipo I/genética , Adolescente , Adulto , Criança , Pré-Escolar , Éxons , Feminino , Heterozigoto , Humanos , Masculino , Pessoa de Meia-Idade , Mutação , Miosite Ossificante/epidemiologia , Miosite Ossificante/genética , Miosite Ossificante/patologia , Espanha/epidemiologia , Adulto Jovem
13.
Eur Arch Paediatr Dent ; 12(6): 318-22, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22122852

RESUMO

BACKGROUND: While it is generally accepted that monozygotic (MZ) twins are identical with respect to inherited traits, because they share 100% of their genetic material, clinical findings and scientific evidence does not support this belief. In addition to environmental factors and stochastic developmental events, a number of genetic mechanisms, detectable by new techniques in molecular genetics, explain the differences frequently observed in MZ twins. CASE REPORT: Nine-year-old twin girls requested treatment for a dental malocclusion. Their facial and occlusal features were very similar. Panoramic radiographs revealed hypodontia of two permanent teeth in one twin (35 and 45) and of only one tooth in the other (45). An incorrect diagnosis of dizygosity (DZ) had been made at birth based on the presence of two amniotic sacs. Despite discordance in the dental complement of both girls their orthodontist suspected that the twins might be identical. A genetic study performed by quantitative fluorescence-polymerase chain reaction (QFPCR) analysis of chromosomes 13, 15, 16, 18, 21, 22, and X confirmed that the twins were MZ. CONCLUSION: Discordances in dental complement between MZ twins are not uncommon and do not exclude monozygosity.


Assuntos
Anodontia/genética , Doenças em Gêmeos , Criança , Feminino , Humanos , Cariótipo , Fenótipo , Reação em Cadeia da Polimerase/métodos , Gêmeos Monozigóticos
14.
Br J Dermatol ; 163(1): 155-61, 2010 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-20184583

RESUMO

BACKGROUND: Dystrophic epidermolysis bullosa (DEB) is a genodermatosis caused by mutations in COL7A1. The clinical manifestations are highly variable from nail dystrophy to life-threatening blistering, making early molecular diagnosis and prognosis of utmost importance for the affected families. Mutation identification is mandatory for prenatal testing. OBJECTIVES: To conduct the first mutational analysis of COL7A1 in a Spanish cohort, to assess mutation consequences at protein/mRNA level and to establish genotype-phenotype correlations. METHODS: Forty-nine Spanish patients with DEB were studied. Antigen mapping was performed on patient skin biopsies. COL7A1 mutation screening in genomic DNA was performed by polymerase chain reaction (PCR) and direct sequencing. Mutation consequences were determined by reverse transcriptase-PCR. RESULTS: Eight patients belonged to three unrelated families with dominant DEB. Forty-one were affected with recessive DEB (RDEB). Specifically, 27 displayed the severe generalized subtype, eight the other generalized subtype and six a localized phenotype (two pretibial, three acral and one inversa). Thirty-five mutations were identified, 20 of which are novel. The pathogenic mutation c.6527insC accounted for 46.3% of Spanish RDEB alleles. A consistent genotype-phenotype correlation was established. CONCLUSIONS: Although the COL7A1 database indicates that most DEB mutations are family specific, the pathogenic mutation c.6527insC was highly recurrent in our cohort. This level of recurrence for a single genetic defect has never previously been reported for COL7A1. Our findings are essential to the clinicians caring for patients with DEB in Spain and in the large population of Spanish descendants in Latin America. They also provide geneticists a molecular clue for a priority mutation screening strategy.


Assuntos
Colágeno Tipo VII/genética , Epidermólise Bolhosa Distrófica/genética , Adolescente , Adulto , Criança , Pré-Escolar , Estudos de Coortes , Análise Mutacional de DNA/métodos , Estudos de Associação Genética , Predisposição Genética para Doença , Humanos , Lactente , Mutação , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Índice de Gravidade de Doença , Espanha , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...